1. Note of clarification of data in the paper entitled association between BRIP1 (BACH1) polymorphisms and breast cancer risk

   • Yadong Wang
   • Haiyan Yang
   • Haiyu Wang

   Editorial 18 March 2015 Pages: 467 - 471

   

2. Overall survival (OS) endpoint: an incomplete evaluation of metastatic breast cancer (MBC) treatment outcome

   • Jacques Raphael
   • S. Verma

   Review 19 March 2015 Pages: 473 - 478

3. Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer

   • X. Zhu
   • L. Shan
   • H. Yang

   Preclinical Study 18 March 2015 Pages: 479 - 486

   

4. Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells

   • Samaya R. Krishnan
   • Binoj C. Nair
   • Ratna K. Vadlamudi

   Preclinical study 19 March 2015 Pages: 487 - 499

   

5. miR-153 inhibits epithelial–mesenchymal transition by targeting metadherin in human breast cancer

   • Wentong Li
   • Limin Zhai
   • Shijun Lv

   Preclinical study 21 March 2015 Pages: 501 - 509

   

6. Prognostic and biological significance of peroxisome proliferator-activated receptor-gamma in luminal breast cancer

   • Rezvan Abduljabbar
   • Methaq Mueen Al-Kaabi
   • Emad Rakha

   Preclinical study 21 March 2015 Pages: 511 - 522

   

7. Differential effects of superoxide dismutase and superoxide dismutase/catalase mimetics on human breast cancer cells

   • Manisha H. Shah
   • Guei-Sheung Liu
   • Hitesh M. Peshavariya

   Preclinical study 21 March 2015 Pages: 523 - 534

   

8. Targeting thyroid hormone receptor beta in triple-negative breast cancer

   • Guowei Gu
   • Luca Gelsomino
   • Suzanne A. W. Fuqua

   Preclinical study 28 March 2015 Pages: 535 - 545

   

9. Retrospective analysis of metastatic behaviour of breast cancer subtypes

   • C. Dilara Savci-Heijink
   • Hans Halfwerk
   • Marc J. van de Vijver

   Preclinical Study Open access 29 March 2015 Pages: 547 - 557

   

10. CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer

    • Sarah J. Conley
    • Trenton L. Baker
    • Max S. Wicha

    Preclinical study 02 April 2015 Pages: 559 - 567

    

11. PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers

    • Jennifer Stanley
    • Lisa Klepczyk
    • Eddy S. Yang

    Preclinical Study 02 April 2015 Pages: 569 - 579

    

12. Quantitative assessment of HER2 amplification in HER2-positive breast cancer: its association with clinical outcomes

    • Qijia Xuan
    • Hongfei Ji
    • Qingyuan Zhang

    Clinical Trial 12 March 2015 Pages: 581 - 588

    

13. Diagnostic accuracy of sentinel node identification is maintained with the addition of local lidocaine and subareolar radioactive colloid injection

    • Vered Stearns
    • Amanda Blackford
    • David Eisner

    Clinical Trial 20 March 2015 Pages: 589 - 595

    

14. The effect of YOCAS©^® yoga for musculoskeletal symptoms among breast cancer survivors on hormonal therapy

    • Luke J. Peppone
    • Michelle C. Janelsins
    • Karen M. Mustian

    Clinical trial 27 March 2015 Pages: 597 - 604

15. Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer

    • Ana Elisa Lohmann
    • Judy-Anne W. Chapman
    • Pamela Jean Goodwin

    Clinical trial 02 April 2015 Pages: 605 - 611

    

16. The association between diabetes and breast cancer stage at diagnosis: a population-based study

    • Lorraine L. Lipscombe
    • Hadas D. Fischer
    • Lawrence Paszat

    Epidemiology 17 March 2015 Pages: 613 - 620

    

17. Impact of breast cancer subtypes and patterns of metastasis on outcome

    • Karin Kast
    • Theresa Link
    • Pauline Wimberger

    Epidemiology 18 March 2015 Pages: 621 - 629

    

18. Cancer risks in Jewish male BRCA1 and BRCA2 mutation carriers

    • Yael Laitman
    • Lital Keinan Boker
    • Eitan Friedman

    Epidemiology 19 March 2015 Pages: 631 - 635

19. Prevalence of PALB2 mutations in the Creighton University Breast Cancer Family Registry

    • C. Snyder
    • K. Metcalfe
    • H. T. Lynch

    Epidemiology 21 March 2015 Pages: 637 - 641

    

20. Short-term weight gain and breast cancer risk by hormone receptor classification among pre- and postmenopausal women

    • Bernard Rosner
    • A. Heather Eliassen
    • Graham A. Colditz

    Epidemiology Open access 22 March 2015 Pages: 643 - 653

    

21. Obesity, body fat distribution, and risk of breast cancer subtypes in African American women participating in the AMBER Consortium

    • Elisa V. Bandera
    • Urmila Chandran
    • Lynn Rosenberg

    Epidemiology 26 March 2015 Pages: 655 - 666

22. Race, response to chemotherapy, and outcome within clinical breast cancer subtypes

    • J. R. Tichy
    • A. M. Deal
    • L. A. Carey

    Epidemiology 27 March 2015 Pages: 667 - 674

    

23. Personality and breast cancer risk and survival: the Miyagi Cohort Study

    • Yuko Minami
    • Toru Hosokawa
    • Ichiro Tsuji

    Epidemiology 01 April 2015 Pages: 675 - 684

24. Targeting exosomes from preadipocytes inhibits preadipocyte to cancer stem cell signaling in early-stage breast cancer

    • Ramkishore Gernapudi
    • Yuan Yao
    • Qun Zhou

    Brief Report 18 March 2015 Pages: 685 - 695

    

25. Erratum to: Platinum-based chemotherapy in triple-negative advanced breast cancer

    • Cynthia Villarreal-Garza
    • Daniel Khalaf
    • Rebecca Dent

    Erratum 26 March 2015 Pages: 697 - 697

    

26. Erratum to: Recurrent mutation testing of BRCA1 and BRCA2 in Asian breast cancer patients identify carriers in those with presumed low risk by family history

    • Peter Choon Eng Kang
    • Sze Yee Phuah
    • Soo Hwang Teo

    Erratum 02 April 2015 Pages: 699 - 700